Morgan Stanley
CSBR icon

Morgan Stanley’s Champions Oncology CSBR Stock Holding History

Morgan Stanley’s Portfolio CSBR Stock Details CSBR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.39M Buy
242,300
+12,641
+6% +$80.3K ﹤0.01% 4971
2025
Q4 		$1.59M Buy
229,659
+40,059
+21% +$267K ﹤0.01% 4948
2025
Q3 		$1.23M Buy
189,600
+59,100
+45% +$416K ﹤0.01% 5074
2025
Q2 		$962K Buy
130,500
+42,068
+48% +$297K ﹤0.01% 5117
2025
Q1 		$768K Buy
88,432
+15,532
+21% +$157K ﹤0.01% 5125
2024
Q4 		$625K Buy
72,900
+15,100
+26% +$76K ﹤0.01% 5333
2024
Q3 		$281K Buy
57,800
+14,700
+34% +$68.9K ﹤0.01% 5622
2024
Q2 		$223K Buy
43,100
+2,400
+6% +$11.7K ﹤0.01% 5616
2024
Q1 		$199K Buy
40,700
+22,500
+124% +$132K ﹤0.01% 5732
2023
Q4 		$102K Buy
18,200
+7,100
+64% +$39.6K ﹤0.01% 6156
2023
Q3 		$68.9K Hold
11,100
– – ﹤0.01% 6034
2023
Q2 		$70.8K Buy
11,100
+2,000
+22% +$10.3K ﹤0.01% 6081
2023
Q1 		$36.6K Buy
9,100
+1,206
+15% +$5.15K ﹤0.01% 6395
2022
Q4 		$35.6K Buy
7,894
+94
+1% +$614 ﹤0.01% 6439
2022
Q3 		$59K Buy
7,800
+2,400
+44% +$20.1K ﹤0.01% 6332
2022
Q2 		$43K Sell
5,400
-1,406
-21% -$10.8K ﹤0.01% 6677
2022
Q1 		$55K Sell
6,806
-728
-10% -$5.84K ﹤0.01% 6658
2021
Q4 		$63K Buy
7,534
+609
+9% +$5.61K ﹤0.01% 6695
2021
Q3 		$70K Sell
6,925
-12,913
-65% -$131K ﹤0.01% 6559
2021
Q2 		$204K Buy
19,838
+3,628
+22% +$36.8K ﹤0.01% 6005
2021
Q1 		$182K Sell
16,210
-3,091
-16% -$35.9K ﹤0.01% 5708
2020
Q4 		$208K Buy
19,301
+3,469
+22% +$35.8K ﹤0.01% 5570
2020
Q3 		$147K Buy
15,832
+2,408
+18% +$21.4K ﹤0.01% 5252
2020
Q2 		$128K Buy
13,424
+3,752
+39% +$32K ﹤0.01% 5286
2020
Q1 		$71K Buy
9,672
+1,638
+20% +$11.5K ﹤0.01% 5326
2019
Q4 		$67K Buy
8,034
+4,534
+130% +$28K ﹤0.01% 5781
2019
Q3 		$20K Hold
3,500
– – ﹤0.01% 6015
2019
Q2 		$27K Hold
3,500
– – ﹤0.01% 5830
2019
Q1 		$34K Sell
3,500
-10,900
-76% -$109K ﹤0.01% 5827
2018
Q4 		$112K Buy
14,400
+10,324
+253% +$119K ﹤0.01% 5511
2018
Q3 		$71K Buy
4,076
+537
+15% +$4.78K ﹤0.01% 5785
2018
Q2 		$22K Buy
3,539
+39
+1% +$187 ﹤0.01% 6126
2018
Q1 		$13K Hold
3,500
– – ﹤0.01% 6211
2017
Q4 		$14K Hold
3,500
– – ﹤0.01% 6157
2017
Q3 		$13K Hold
3,500
– – ﹤0.01% 6122
2017
Q2 		$9K Hold
3,500
– – ﹤0.01% 6261
2017
Q1 		$11K Buy
+3,500
New +$12.2K ﹤0.01% 6210
2016
Q3 		– Sell
-2,690
Closed -$6K – 6512
2016
Q2 		$6K Sell
2,690
-137
-5% -$428 ﹤0.01% 6175
2016
Q1 		$10K Sell
2,827
-124
-4% -$457 ﹤0.01% 6127
2015
Q4 		$10K Buy
2,951
+261
+10% +$1.12K ﹤0.01% 6237
2015
Q3 		$14K Buy
+2,690
New +$17.6K ﹤0.01% 6155

Other funds holding CSBR

BMC
Battery Management Corp Boston, Massachusetts $426M AUM 21.5% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MBAM
Mink Brook Asset Management West Palm Beach, Florida $179M AUM 37.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Morgan Stanley's CSBR Position: Q1 2026 in Review

Morgan Stanley increased its Champions Oncology (CSBR) stake by 5.5% in Q1 2026, buying an estimated $80.3K and bringing the position to 242,300 shares worth $1.39M. The position accounts for ﹤0.01% of the portfolio, ranked #4971.

Morgan Stanley first reported a position in CSBR in Q3 2015 and has held it in 41 quarters since. The position peaked at $1.59M in Q4 2025. 25 funds tracked by Wall St. Rank hold CSBR as of Q1 2026.

  • Morgan Stanley held 242,300 shares of Champions Oncology worth $1.39M as of Q1 2026.
  • Morgan Stanley bought 12,641 Champions Oncology shares in Q1 2026, an estimated $80.3K.
  • Champions Oncology made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #4971 holding.
  • Morgan Stanley first reported a position in Champions Oncology in Q3 2015 and has held it in 41 quarters since.
  • Morgan Stanley's Champions Oncology position peaked at $1.59M in Q4 2025.
  • 25 funds tracked by Wall St. Rank held Champions Oncology as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.